Efforts to more formally develop testing guidelines were extended by the Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group in 2007.20 This initiative was established by the Centers for Disease Control (CDC) Office of Public Health Genomics in 2004, with the goal of establishing and evaluating evidence for pharmacogenomic testing in a systematic manner. To date, the only assessment of neuropsychiatric medications conducted by this group was an examination in 2007 of evidence for CYP2D6 testing in adults with nonpsychotic depression who were being considered for treatment with a selective serotonin reuptake inhibitor (SSRI). 20 After reviewing the available evidence, the panel concluded that pharmacogenomic testing in adults initiating SSRI treatment for depression was not recommended at that time (2007). Furthermore, the EGAPP initiative could not endorse the clinical utility of pharmacogenomic testing for SSRIs and identified the need for additional prospective, double-blind clinical trials to expand the evidence in support of pharmacogenomic testing.
